Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
2(40%)
Results Posted
50%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_4
2
40%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 42 (66.7%)

Trials by Status

completed240%
recruiting240%
terminated120%

Recent Activity

2 active trials
Showing 5 of 5
completed

A Prospective Real World Study of Rimegepant in the Treatment of Migraine

NCT05709106
recruiting

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

NCT06409832
recruitingphase_4

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

NCT07301008
terminatedphase_4

Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine

NCT05211154
completedphase_3

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

NCT05399459

Clinical Trials (5)

Showing 5 of 5 trials
NCT05709106

A Prospective Real World Study of Rimegepant in the Treatment of Migraine

Completed
NCT06409832

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Recruiting
NCT07301008Phase 4

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

Recruiting
NCT05211154Phase 4

Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine

Terminated
NCT05399459Phase 3

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5